非アルコール性脂肪性肝炎（NASH）の疫学分析と2032年までの予測

非アルコール性脂肪性肝炎（NASH）は非アルコール性脂肪性肝疾患（NAFLD）のサブタイプであり、肝細胞障害と炎症が特徴です。NASHは無症状のことが多く、偶発的に発見されます。診断には肝生検が必要です。NASHは肝線維化の有無にかかわらず発症し、より重篤な肝疾患に進行する可能性があります。NASH患者の20％は肝硬変を発症し、すべてのNASH患者は肝細胞癌のリスクが高くなります。

当レポートでは、主要7ヶ国市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）における非アルコール性脂肪性肝炎（NASH）の危険因子、併存疾患、世界および過去の疫学動向について概説し、非アルコール性脂肪性肝炎（NASH）の診断済み発症例と診断済み有病率に関する10年間の疫学予測などをまとめています。

目次

第1章 非アルコール性脂肪性肝炎：エグゼクティブサマリー

第2章 疫学

• 病気の背景
• 危険因子と併存疾患
• 世界的および歴史的動向
• 主要7ヶ国予測調査手法
• 非アルコール性脂肪性肝炎の疫学予測（2022年～2032年）
  • NASHの診断済み症例件数
  • NASHの診断済み発症例、年齢別
  • NASHの診断済み発症例、性別
  • NASHの診断済み罹患症例、線維症段階別
  • NASHに起因する診断済み肝硬変の蔓延症例
• 議論
  • 疫学予測の洞察
  • 肥満
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

List of Tables

• Table 1: Summary of newly added data types
• Table 2: Summary of updated data types
• Table 3: Non-alcoholic fatty liver disease activity score
• Table 4: Risk factors and comorbidities for CKD
• Table 5: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

List of Figures

• Figure 1: 7MM, diagnosed prevalent cases of NASH, both sexes, N, all ages, 2022 and 2032
• Figure 2: 7MM, diagnosed prevalence of NASH, both sexes, %, all ages, 2012-32
• Figure 3: 7MM, sources used to forecast the diagnosed prevalent cases of NAFLD
• Figure 4: 7MM, sources used to forecast the total prevalent cases of NAFLD
• Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of NASH
• Figure 6: 7MM, sources used to forecast diagnosed prevalent cases of NASH by fibrosis stage
• Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of NASH by cirrhosis type
• Figure 8: 7MM, diagnosed prevalent cases of NASH, N, men and women, all ages, 2022
• Figure 9: 7MM, diagnosed prevalent cases of NASH by age, N, men and women, 2022
• Figure 10: 7MM, diagnosed prevalent cases of NASH by sex, N, all ages, 2022
• Figure 11: 7MM, diagnosed prevalent cases of NASH by fibrosis stage, N, men and women, all ages, 2022
• Figure 12: 7MM, diagnosed prevalent cases of cirrhosis attributable to NASH, N, men and women, all ages, 2022

Abstract

Non-alcoholic steatohepatitis (NASH) is a subtype of non-alcoholic fatty liver disease (NAFLD) that is characterized by liver cell damage and inflammation (Sheka et al., 2020). NASH is often asymptomatic and is detected incidentally. A liver biopsy is required for diagnosis. NASH can occur with or without liver fibrosis and can progress to more serious liver disease. A total of 20% of NASH patients will develop cirrhosis and all NASH patients are at increased risk for hepatocellular carcinoma (Sheka et al., 2020).

Scope

• Non-alcoholic steatohepatitis report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for NASH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of NASH. The diagnosed prevalent cases of NASH are segmented by age and sex. Additionally, the forecast is further segmented based on fibrosis stage and cirrhosis type. This report also provides the historical and 10-year forecasted total and diagnosed prevalent cases of NAFLD.

Reasons to Buy

The NASH Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global NASH markets.
• Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
• Understand magnitude of the NASH population by age, sex, fibrosis stage, and cirrhosis type.

Table of Contents

Table of Contents

• About GlobalData

1 Non-Alcoholic Steatohepatitis: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Forecast assumptions and methods
  • 2.4.2 Forecast assumptions and methods: diagnosed prevalent cases of NAFLD
  • 2.4.3 Forecast assumptions and methods: total prevalent cases of NAFLD
  • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NASH
  • 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of NASH by fibrosis stage.
  • 2.4.6 Forecast assumptions and methods: diagnosed prevalent cases of NASH with compensated and decompensated cirrhosis.
• 2.5 Epidemiological forecast for non-alcoholic steatohepatitis (2022-32)
  • 2.5.1 Diagnosed prevalent cases of NASH.
  • 2.5.2 Age-specific diagnosed prevalent cases of NASH
  • 2.5.3 Sex-specific diagnosed prevalent cases of NASH
  • 2.5.4 Diagnosed prevalent cases of NASH by fibrosis stage.
  • 2.5.5 Diagnosed prevalent cases of cirrhosis attributable to NASH.
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 Obesity omission
  • 2.6.3 COVID-19 impact.
  • 2.6.4 Limitations of the analysis
  • 2.6.5 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary research - high-prescriber survey
• 3.3 About the Authors
  • 3.3.1 Epidemiologist
  • 3.3.2 Reviewers
  • 3.3.3 Vice President of Disease Intelligence and Epidemiology
• Contact Us